Citations

Showing 10 of 108083 citations.

Improving the Specificity of Cardiac Biomarkers—The Early Development of Cardiac Troponin I (cTnI) Assays
Jaffe, Allan S. , Jaffe, Allan S.

Mayo Clinic

Clinical Chemistry | October 12, 2017 | Volume: 64 | Issue: 3 | Pages: 609-610

10.1373/clinchem.2017.272906 | PMID 29021328 Get It

Physiology in Perspective: Physiology Provides Insight into Health
Sieck, Gary C. , Sieck, Gary

Mayo Clinic

Physiology | October 12, 2017 | Volume: 32 | Issue: 6 | Pages: 408-409

10.1152/physiol.00024.2017 | PMID 29021360 Get It

Lactic Acid: No Longer an Inert and End-Product of Glycolysis
Sun, Shiren , Chen, Jianghua , Qian, Qi , Li, Heng

Mayo Clinic

Physiology | October 12, 2017 | Volume: 32 | Issue: 6 | Pages: 453-463

10.1152/physiol.00016.2017 | PMID 29021365 Get It

For decades, lactic acid has been considered a dead-end product of glycolysis. Research in the last 20+ years has shown otherwise. Through its transporters (MCTs) and receptor (GPR81), lactic acid plays a key role in multiple cellular processes, including energy regulation, immune tolerance, memory formation, wound healing, ischemic tissue injury, and cancer growth and metastasis. We summarize key findings of lactic acid signaling, functions, and many remaining questions.
Machine Learning and Rare Variant Adjudication in Type 1 Long QT Syndrome
Giudicessi, John R.

Mayo Clinic

Circulation: Cardiovascular Genetics | October 12, 2017 | Volume: 10 | Issue: 5 | Pages: No page available

10.1161/circgenetics.117.001944 | PMID 29021308 Get It

Assessment of the Patient With Severe Aortic Stenosis
Pellikka, Patricia A. , Pellikka, Patricia A

Mayo Clinic

Circulation: Cardiovascular Imaging | October 12, 2017 | Volume: 10 | Issue: 10 | Pages: No page available

10.1161/circimaging.117.007084 | PMID 29021265 Get It

Benefits of Cardiac Rehabilitation on Cardiovascular Outcomes in Patients With Diabetes Mellitus After Percutaneous Coronary Intervention
Jiménez‐Navarro, Manuel F. , Pérez‐Belmonte, Luis M. , Lennon, Ryan J. , Diaz-Melean, Carlos M, Rodriguez-Escudero, Juan P., Crusan, Daniel J. , Prasad, Abhiram , Squires, Ray W. , Diaz-Melean, Carlos, Crusan, Daniel, López-Jiménez, Francisco , Lennon, Ryan J. , Goel, Kashish , Thomas, Randal J. , Prasad, Abhiram

Mayo Clinic

Journal of the American Heart Association | October 12, 2017 | Volume: 6 | Issue: 10 | Pages: No page available

10.1161/jaha.117.006404 | PMID 29021270 Get It

Background Participation in cardiac rehabilitation ( CR ) is an essential component of care for patients with coronary artery disease. However, little is known about its benefit on cardiovascular outcomes in patients with diabetes mellitus ( DM ) who have undergone percutaneous coronary intervention. The aim of our study was to evaluate the impact of CR in this high‐risk group of patients. Methods and Results We performed a retrospective analysis of all patients with DM who underwent percutaneous coronary intervention in Olmsted County (Minnesota) between 1994 and 2010, assessing the impact of CR participation on clinical outcomes. CR participation was significantly lower in patients with DM (38%, 263/700) compared with those who did not have DM (45%, 1071/2379; P =0.004). Using propensity score adjustment, we found that in patients with DM , CR participation was associated with significantly reduced all‐cause mortality (hazard ratio, 0.56; 95% confidence interval, 0.39–0.80; P =0.002) and composite end point of mortality, myocardial infarction, or revascularization (hazard ratio, 0.77; 95% confidence interval, 0.60–0.98; P =0.037), during a median follow‐up of 8.1 years. In patients without DM , CR participation was associated with a significant reduction in all‐cause mortality (hazard ratio, 0.67; 95% confidence interval, 0.55–0.82; P <0.001) and cardiac mortality (hazard ratio, 0.67; 95% confidence interval, 0.47–0.95; P =0.024). Conclusions CR participation after percutaneous coronary intervention is associated with lower all‐cause mortality rates in patients with DM , to a similar degree as for those without DM . However, CR participation was lower in patients with DM , suggesting the need to identify and correct the barriers to CR participation for this higher‐risk group of patients.
Erratum: Arthritis Progression on Serial MRIs Following Diagnosis of Medial Meniscal Posterior Horn Root Tear
Johnson, Nick, Mohan, Rohith , Littrell, Laurel A. , Collins, Mark S., Krych, Aaron J. , Johnson, Nick R., Krych, Aaron J , Hevesi, Mario , Stuart, Michael J.

Mayo Clinic

The Journal of Knee Surgery | October 11, 2017 | Volume: 31 | Issue: 07 | Pages: e1-e1

10.1055/s-0037-1607351 | PMID 29020692 Get It

A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer
Ciombor, Kristen K. , Bekaii‐Saab, Tanios , Bekaii-Saab, Tanios S

Mayo Clinic

The Oncologist | October 11, 2017 | Volume: 23 | Issue: 1 | Pages: 25-34

10.1634/theoncologist.2017-0203 | PMID 29021377 Get It

Abstract The emergence of targeted therapies for the treatment of metastatic colorectal cancer (mCRC) has considerably improved survival, but has also resulted in a dilemma of identifying the optimal sequence and combination of various agents in the mCRC treatment landscape. A number of cytotoxic agents, including irinotecan, oxaliplatin, 5-fluorouracil, capecitabine, and TAS-102, are available for treatment of mCRC. Additionally, whereas patients harboring rat sarcoma viral oncogene homolog (RAS)–wild type mCRC can be treated with the anti-epidermal growth factor receptor antibodies cetuximab and panitumumab or antiangiogenic agents (bevacizumab, ziv-aflibercept, and ramucirumab), patients with RAS-mutant mCRC are limited to antiangiogenic agents as biologic options. Regorafenib, a multikinase inhibitor, can be used in both RAS subgroups. As such, the recommended sequence of therapies that should be received by each subgroup must also be considered separately. This review provides an overview of recent clinical data for approved and investigational targeted therapies that have been studied across different mCRC treatment lines and patient subgroups. It also examines emerging trends in the treatment landscape for mCRC, including treatment with immune checkpoint inhibitors and the utilization of genomic profiling. Implications for Practice Currently, there are no established guidelines for optimal sequencing of cytotoxic or targeted agents in metastatic colorectal cancer (mCRC). This review provides a snapshot of the current mCRC treatment paradigm and examines the latest clinical data that support the utilization of several targeted agents alone or in combination with backbone chemotherapy across different lines of treatment and patient populations, highlighting recommendations for their usage. Recent advances in the treatment landscape are also summarized, including genomic profiling and preliminary results with immune checkpoint inhibitors.
Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control
Chertow, Glenn M. , Cheung, Alfred K. , Greene, Tom , Wei, Guo , Campbell, Ruth , Conroy, Margaret, Haley, William E. , Horwitz, Edward , Kitzman, Dalane W. , Lash, James P. , Pisoni, Roberto, Riessen, Erik, Rosendorff, Clive , Watnick, Suzanne , Whittle, Jeff , Whelton, Paul K. , Haley, William, Greene, Tom , Beddhu, Srinivasan , Cushman, William C. , Rahman, Mahboob , Freedman, Barry I. , Papademetriou, Vasilios

Mayo Clinic

Circulation | October 11, 2017 | Volume: 137 | Issue: 2 | Pages: 134-143

10.1161/circulationaha.117.030848 | PMID 29021322 Get It

Background: In individuals with a low diastolic blood pressure (DBP), the potential benefits or risks of intensive systolic blood pressure (SBP) lowering are unclear. Methods: SPRINT (Systolic Blood Pressure Intervention Trial) was a randomized controlled trial that compared the effects of intensive (target <120 mm Hg) and standard (target <140 mm Hg) SBP control in 9361 older adults with high blood pressure at increased risk of cardiovascular disease. The primary outcome was a composite of cardiovascular disease events. All-cause death and incident chronic kidney disease were secondary outcomes. This post hoc analysis examined whether the effects of the SBP intervention differed by baseline DBP. Results: Mean baseline SBP and DBP were 139.7±15.6 and 78.1±11.9 mm Hg, respectively. Regardless of the randomized treatment, baseline DBP had a U-shaped association with the hazard of the primary cardiovascular disease outcome. However, the effects of the intensive SBP intervention on the primary outcome were not influenced by baseline DBP level ( P for interaction=0.83). The primary outcome hazard ratio for intensive versus standard treatment was 0.78 (95% confidence interval, 0.57–1.07) in the lowest DBP quintile (mean baseline DBP, 61±5 mm Hg) and 0.74 (95% confidence interval, 0.61–0.90) in the upper 4 DBP quintiles (mean baseline DBP, 82±9 mm Hg), with an interaction P value of 0.78. Results were similar for all-cause death and kidney events. Conclusions: Low baseline DBP was associated with increased risk of cardiovascular disease events, but there was no evidence that the benefit of the intensive SBP lowering differed by baseline DBP. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01206062.
Prevalence and Outcomes of Left‐Sided Valvular Heart Disease Associated With Chronic Kidney Disease
Samad, Zainab , Sivak, Joseph A. , Phelan, Matthew, Schulte, Phillip J. , Patel, Uptal D. , Velazquez, Eric J.

Mayo Clinic

Journal of the American Heart Association | October 11, 2017 | Volume: 6 | Issue: 10 | Pages: No page available

10.1161/jaha.117.006044 | PMID 29021274 Get It

Background Chronic kidney disease ( CKD ) is an adverse prognostic marker for valve intervention patients; however, the prevalence and related outcomes of valvular heart disease in CKD patients is unknown. Methods and Results Included patients underwent echocardiography (1999–2013), had serum creatinine values within 6 months before index echocardiogram, and had no history of valve surgery. CKD was defined as diagnosis based on the International Classification of Diseases, Ninth Revision or an estimated glomerular filtration rate <60 mL/min per 1.73 m 2 . Qualitative assessment determined left heart stenotic and regurgitant valve lesions. Cox models assessed CKD and aortic stenosis ( AS ) interaction for subsequent mortality; analyses were repeated for mitral regurgitation ( MR ). Among 78 059 patients, 23 727 (30%) had CKD ; of these, 1326 were on hemodialysis. CKD patients were older; female; had a higher prevalence of hypertension, hyperlipidemia, diabetes, history of coronary artery bypass grafting/percutaneous coronary intervention, atrial fibrillation, and heart failure ≥mild AS; and ≥mild MR (all P <0.001). Five‐year survival estimates of mild, moderate, and severe AS for CKD patients were 40%, 34%, and 42%, respectively, and 69%, 54%, and 67% for non‐CKD patients. Five‐year survival estimates of mild, moderate, and severe MR for CKD patients were 51%, 38%, and 37%, respectively, and 75%, 66%, and 65% for non‐CKD patients. Significant interaction occurred among CKD , AS / MR severity, and mortality in adjusted analyses; the CKD hazard ratio increased from 1.8 (non‐ AS patients) to 2.0 (severe AS ) and from 1.7 (non‐ MR patients) to 2.6 (severe MR ). Conclusions Prevalence of at least mild AS and MR is substantially higher and is associated with significantly lower survival among patients with versus without CKD . There is significant interaction among CKD , AS / MR severity, and mortality, with increasingly worse outcomes for CKD patients with increasing AS / MR severity.